Metabolic DiseaseEli Lilly
Eli Lilly Tirzepatide Demonstrates Significant Improvement in Obstructive Sleep Apnea
BMI
Biotechnology Media Insights
Editorial Team · March 18, 2025
Eli Lilly announces positive SURMOUNT-OSA trial results showing tirzepatide significantly reduces sleep apnea severity in adults with obesity.
Eli Lilly today announced positive results from the SURMOUNT-OSA Phase 3 trial evaluating tirzepatide in adults with moderate-to-severe obstructive sleep apnea (OSA) and obesity. The trial met its primary endpoint, with tirzepatide demonstrating a significant reduction in the apnea-hypopnea index (AHI) compared to placebo.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.